Glaucoma-Related Adverse Events at 10 Years in the Infant Aphakia Treatment Study: A Secondary Analysis of a Randomized Clinical Trial.


Journal

JAMA ophthalmology
ISSN: 2168-6173
Titre abrégé: JAMA Ophthalmol
Pays: United States
ID NLM: 101589539

Informations de publication

Date de publication:
01 02 2021
Historique:
pubmed: 18 12 2020
medline: 27 4 2021
entrez: 17 12 2020
Statut: ppublish

Résumé

Glaucoma-related adverse events constitute serious complications of cataract removal in infancy, yet long-term data on incidence and visual outcome remain lacking. To identify and characterize incident cases of glaucoma and glaucoma-related adverse events (glaucoma + glaucoma suspect) among children in the Infant Aphakia Treatment Study (IATS) by the age of 10.5 years and to determine whether these diagnoses are associated with optic nerve head (ONH) and peripapillary retinal nerve fiber layer (RNFL) assessment. Analysis of a multicenter randomized clinical trial of 114 infants with unilateral congenital cataract who were aged 1 to 6 months at surgery. Data on long-term glaucoma-related status and outcomes were collected when children were 10.5 years old (July 14, 2015, to July 12, 2019) and analyzed from March 30, 2019, to August 6, 2019. Participants were randomized at cataract surgery to either primary intraocular lens (IOL), or aphakia (contact lens [CL]). Standardized definitions of glaucoma and glaucoma suspect were created for IATS and applied for surveillance and diagnosis. Development of glaucoma and glaucoma + glaucoma suspect in operated-on eyes up to age 10.5 years, plus intraocular pressure, axial length, RNFL (by optical coherence tomography), and ONH photographs. In Kaplan-Meier analysis, for all study eyes combined (n = 114), risk of glaucoma after cataract removal rose from 9% (95% CI, 5%-16%) at 1 year, to 17% (95% CI, 11%-25%) at 5 years, to 22% (95% CI, 16%-31%) at 10 years. The risk of glaucoma plus  glaucoma suspect diagnosis after cataract removal rose from 12% (95% CI, 7%-20%) at 1 year, to 31% (95% CI, 24%-41%) at 5 years, to 40% (95% CI, 32%-50%) at 10 years. Risk of glaucoma and glaucoma plus glaucoma suspect diagnosis at 10 years was not significantly different between treatment groups. Eyes with glaucoma (compared with eyes with glaucoma suspect or neither) had longer axial length but relatively preserved RNFL and similar ONH appearance and visual acuity at age 10 years. Risk of glaucoma-related adverse events continues to increase with longer follow-up of children following unilateral cataract removal in infancy and is not associated with primary IOL implantation. Development of glaucoma (or glaucoma suspect) after removal of unilateral congenital cataract was not associated with worse visual acuity outcomes at 10 years. ClinicalTrials.gov Identifier: NCT00212134.

Identifiants

pubmed: 33331850
pii: 2774257
doi: 10.1001/jamaophthalmol.2020.5664
pmc: PMC7747044
doi:

Banques de données

ClinicalTrials.gov
['NCT00212134']

Types de publication

Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

165-173

Subventions

Organisme : NEI NIH HHS
ID : UG1 EY013287
Pays : United States
Organisme : NEI NIH HHS
ID : UG1 EY013272
Pays : United States
Organisme : NEI NIH HHS
ID : UG1 EY025553
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY026877
Pays : United States

Auteurs

Sharon F Freedman (SF)

Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina.

Allen D Beck (AD)

Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia.

Azhar Nizam (A)

Department of Biostatistics and Bioinformatics, Rollins School of Public Health of Emory University, Atlanta, Georgia.

Deborah K Vanderveen (DK)

Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.

David A Plager (DA)

Department of Ophthalmology, Indiana University School of Medicine, Indianapolis.

David G Morrison (DG)

Department of Ophthalmology and Visual Sciences, Vanderbilt University Medical Center, Nashville, Tennessee.

Carolyn D Drews-Botsch (CD)

Department of Biostatistics and Bioinformatics, Rollins School of Public Health of Emory University, Atlanta, Georgia.

Scott R Lambert (SR)

Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH